IP Library Granted Patent US 11,439,699
Granted Patent B2
US 11,439,699 · App. 16/921,243 · Granted Sep 13, 2022

Polypeptides of

Inventors: Charles Nelson Carver, III (Spicer, MN); Daryll A. Emery (New London, MN)
Assignee: Epitopix, LLC
A61K39/114A61K39/39A61P31/04C07K14/195G01N33/56911C12N2500/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,439,699
App. No.
16/921,243
Granted
Sep 13, 2022
Kind
B2
Abstract

The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Claims (27)

1. A composition comprising an isolated polypeptide having at least 85% similarity to amino acids 63-423 of SEQ ID NO:2; and

a pharmaceutically acceptable adjuvant.

2. The composition of claim 1 further comprising:

isolated polypeptides having molecular weights of 92 kDa to 79 kDa, 73 kDa to 63 kDa, 62 kDa to 58 kDa, and 57 kDa to 47 kDa, wherein the polypeptides are isolatable from a Fusobacterium necrophorum subsp. necrophorum , when incubated in media comprising an iron chelator and not isolatable when grown in the media without the iron chelator, wherein the iron chelator is 2,2′-dipyridyl, and wherein molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions,

isolated polypeptides having molecular weights of 108 kDa to 98 kDa and 79 kDa to 69 kDa, wherein the polypeptides are isolatable from a Fusobacterium necrophorum subsp. necrophorum when incubated in media comprising an iron chelator, are expressed by the Fusobacterium necrophorum subsp. necrophorum when incubated in media without the iron chelator and expressed at an enhanced level during growth in media comprising an iron chelator, wherein the iron chelator is 2,2′-dipyridyl, and wherein molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions; and

a pharmaceutically acceptable adjuvant.

3. The composition of claim 1 further comprising a protein having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4.

4. The composition of claim 1 further comprising a protein having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.

5. The composition of claim 1 further comprising a protein having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4, and a protein having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.

6. A method comprising:

administering to a subject an amount of the composition of claim 1 effective to induce the subject to produce antibody that specifically binds to at least one polypeptide of the composition.

7. A method for treating an infection in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.

8. A method for treating a symptom in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.

9. A method for decreasing colonization in a subject, the method comprising:

administering an effective amount of the composition of claim 1 to a subject colonized by or at risk of being colonized by a Fusobacterium spp.

10. The method of claim 6 wherein the subject is a mammal.

11. The method of claim 10 wherein the mammal is a human, bovine, or ovine.

12. The method of claim 7 wherein the Fusobacterium spp. is F. necrophorum.

13. The method of claim 6 wherein at least 10 micrograms (μg) and no greater than 2000 μg of polypeptide is administered.

14. The method of claim 7 wherein the infection causes a condition selected from metritis, hepatic abscesses, and foot rot.

15. A kit for detecting antibody that specifically binds a polypeptide, comprising in separate containers:

the isolated polypeptide of claim 1 ; and

a reagent that detects an antibody that specifically binds the polypeptide.

16. A composition comprising:

a recombinant host cell that comprises a recombinant polypeptide having at least 85% similarity to amino acids 63 through 423 of SEQ ID NO:2; and a pharmaceutically acceptable adjuvant.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2020
From: CARVER, CHARLES NELSON, III; EMERY, DARYLL A.
To: EPITOPIX, LLC
Reel/Frame 053917/0752 →
Continuity (3)
Continuation 15774168
Provisional Application 62252951 · Nov 9, 2015
Related Publication 20210023194A1 · Jan 28, 2021